The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
Martin McCabe
Consulting or Advisory Role - Amgen (Inst)
Laura Kirton
No Relationships to Disclose
Maria Khan
No Relationships to Disclose
Nicola Fenwick
No Relationships to Disclose
Sandra J. Strauss
Consulting or Advisory Role - Ceridwen Oncology; GlaxoSmithKline
Claudia Valverde
Consulting or Advisory Role - Bayer; Eisai; GlaxoSmithKline; Lilly; Mundipharma; Pfizer; PharmaMar
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar; ROVI
Cristina Mata
No Relationships to Disclose
Nathalie Gaspar
Consulting or Advisory Role - Eisai; IPSEN
Travel, Accommodations, Expenses - Eisai
Roberto Luksch
No Relationships to Disclose
Alessandra Longhi
No Relationships to Disclose
Uta Dirksen
Consulting or Advisory Role - Ipsen; Lilly (Inst)
Marianne Phillips
No Relationships to Disclose
Akmal Safwat
No Relationships to Disclose
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
Thomas Kuehne
Consulting or Advisory Role - Amgen; Novartis; SOBI; UCB
Research Funding - Amgen (Inst); Novartis (Inst)
Expert Testimony - Amgen
Jukka Kanerva
Stock and Other Ownership Interests - Orion
Consulting or Advisory Role - Bayer
Andrew J. Westwood
No Relationships to Disclose
Stefano Ferrari
No Relationships to Disclose
Jeremy Whelan
No Relationships to Disclose
Keith Wheatley
Research Funding - Bayer (Inst); Bio-Cancer Treatment International (Inst); EUSA Pharma (Inst); Roche (Inst)